Breakthrough trial targets aggressive stomach cancers with new drug combo
NCT ID NCT06093425
Summary
This study is testing whether adding an experimental drug called TST001 to standard chemotherapy and immunotherapy works better for advanced stomach or gastroesophageal junction cancer. It will involve 820 adults whose tumors have a specific marker called Claudin18.2. The goal is to see if this three-drug combination can better control the cancer and help patients live longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.